A
Acticor Biotech SA
PAR:ALACT
Acticor Biotech SA
PAR:ALACT
Price:
0.926 EUR
-18.77%
Market Closed
Updated:
May 16, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of ALACT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ALACT
Relative Value
Base Case
Not Available
A
Valuation Multiples
Multiples Across Competitors
ALACT Competitors Multiples
Acticor Biotech SA Competitors
Acticor Biotech SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| FR |
A
|
Acticor Biotech SA
PAR:ALACT
|
14.6m EUR | 0 | -0.8 | -0.8 | -0.8 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.2B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 5.7 | 44.6 | 18.8 | 30.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.5B USD | 11.4 | 31.1 | 25.1 | 26.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.4B USD | 8.2 | 27.8 | 22.5 | 25 | |
| AU |
|
CSL Ltd
ASX:CSL
|
138.6B AUD | 6.6 | 37.6 | 22.6 | 28.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.1B USD | 3.1 | 173.8 | 7 | 9.2 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.3B USD | 9.7 | -8.4 | -9.3 | -8.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.3B USD | 3.4 | 28.5 | 14.5 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 18.4 | 74.7 | 45.7 | 62.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
